Brief: Jazz Pharmaceuticals Announces FDA Acceptance And Priority Review Of Supplemental Biologics License Application For Ziihera®
27/04/2026 14:03
April 27 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS IN FIRST-LINE HER2+ LOCALLY ADVANCED OR METASTATIC GEA JAZZ PHARMACEUTICALS PLC - FDA SETS PDUFA DATE OF AUGUST 25, 2026 FOR ZIIHERA SBLA Source text: ID:nPn3rRwcja Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032